Literature DB >> 19667608

Imiquimod as an immune response modulator in infectious conditions.

Robert B Skinner1.   

Abstract

Imiquimod 5% cream is approved in the United States as a patient-applied treatment for external genital and perianal warts (condyloma accuminata) in adults and in children as young as 12 years of age. As noted in the Introduction by Dr Rosen, imiquimod functions as an immune enhancer. Local activation of portions of both the cell-mediated and innate arms of the acquired immune system yields antiviral and antitumor activity. Imiquimod's ability to use the host's immune system to treat cutaneous viral infections and tumors has led to many off-label uses. This section will review the published studies and case reports for the approved indication of genital warts, as well as the use of imiquimod in treating common and plantar warts, flat warts, molluscum contagiosum, and leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 19667608     DOI: 10.3810/pgm.12.2002.suppl23.120

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  1 in total

1.  Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.

Authors:  Konstantinos Poulas; Konstantinos Farsalinos; Charilaos Zanidis
Journal:  Front Immunol       Date:  2020-06-11       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.